chartexchange

CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors

GlobeNewswire Inc. | Nov 12, 2026 8:30 AM EST

VANCOUVER, Washington, Nov. 12, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced that a private investor has made an additional $5 million investment into the Company in support of its clinical development of leronlimab.

Read original article